Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 11/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 0.50 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.49 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4933545 | 0.91 | ALDH1A1 (0.46) | L3MBTL3L3MBTL1CYP2C9HRH3KDM4E | |
| SCHEMBL4937138 | 0.88 | HRH3 (0.43) | CYP2C9HRH3KDM4EALDH1A1WDR5 | |
| SCHEMBL10263755 | 0.79 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1MBTD1TP53BP1CYP2C9 | |
| SCHEMBL4939123 | 0.76 | ALDH1A1 (0.56) | L3MBTL3L3MBTL1MBTD1TP53BP1HRH3 | |
| SCHEMBL4941322 | 0.74 | PARP1 (0.43) | L3MBTL3L3MBTL1MBTD1TP53BP1HRH3 | |
| SCHEMBL4937515 | 0.74 | ALDH1A1 (0.46) | CYP2C9HRH3ALDH1A1GAA | |
| SCHEMBL14282077 | 0.73 | HRH3 (0.44) | L3MBTL3L3MBTL1MBTD1TP53BP1HRH3 | |
| SCHEMBL10157709 | 0.73 | MAPT (0.47) | L3MBTL3L3MBTL1MBTD1HRH3KDM4E | |
| SCHEMBL15759210 | 0.73 | L3MBTL3 (0.45) | L3MBTL3L3MBTL1MBTD1HRH3KDM4E | |
| SCHEMBL4937299 | 0.72 | MAPT (0.46) | L3MBTL3L3MBTL1MBTD1HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556046-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2005-07-27 | — | — | EP | claimed |
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-06 | — | — | US | claimed |
| WO-2004037257-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | claimed |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | APODACA RICHARD L | 2008-01-03 | — | — | US | disclosed |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | APODACA RICHARD L | 2008-01-03 | — | — | US | disclosed |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | APODACA RICHARD L | 2008-01-03 | — | — | US | disclosed |
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | disclosed |
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | disclosed |
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | disclosed |
| EP-1556046-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004037257-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | HRH2, HNMT, HRH3 | L3MBTL3 4833/4885L3MBTL1 4814/4885MBTD1 3982/4885 |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | HRH2, HNMT, HRH3 | L3MBTL3 4833/4885L3MBTL1 4814/4885MBTD1 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.